ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Beta-blocker (95% CI) indirectness, imprecision HF hospitalisation - CKD class 3a 669 VERY LOWb,c,f due to risk of bias, indirectness, imprecision Overalld (from 5 fewer to 88 fewer) HF hospitalisation - CKD class 3b-4 450 VERY LOWb,c,f due to risk of bias, indirectness, imprecision Overalld (from 101 fewer to 25 more) Renal failure (not defined) 886 LOWb due to risk of bias Not estimableg Not estimabl eg Not estimableg VERY LOWb,c due to risk of bias, imprecision (from 8 fewer to 44 more) VERY LOWb,c due to risk of bias, imprecision Peto Odds (from 0 more to 10 more)i a Control risk taken from MERIT-HF b Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias c Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs d Data insufficient to calculate control risk. Overall risk given e Downgraded by 1 increment due to indirectness as a compound outcome was reported rather than numbers of admissions Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 